GlycoMimetics (GLYC) AI Stock Analysis

• Market Cap: $10.13M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: -100.00%
• EPS Growth: -0.58%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 645,321
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: >-0.01
• Price to Book (P/B): 9.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -77.58
• Enterprise Value/Market Cap: 66.52
• Enterprise Value/Revenue: 2.18
• Enterprise Value/Gross Profit: 4.54
• Enterprise Value/Ebitda: 14.29
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: ―

GlycoMimetics is facing major financial hurdles with a lack of revenue and ongoing losses, placing substantial risk on its operations. The recent negative corporate events add to the uncertainty and challenge investor confidence. Despite some short-term technical momentum, the overall outlook is weak due to the absence of profitability and unattractive valuation metrics.

GlycoMimetics Business Overview & Revenue Model

Company Description

GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases that involve abnormal carbohydrate interactions. Operating primarily in the biopharmaceutical sector, GlycoMimetics develops its proprietary drug candidates targeting cancer and inflammatory diseases. Its lead product candidates include uproleselan, an E-selectin antagonist for the treatment of acute myeloid leukemia (AML), and other drugs in earlier stages of development.

How the Company Makes Money

GlycoMimetics generates revenue primarily through research and development collaborations, milestone payments, and licensing agreements with larger pharmaceutical companies. These partnerships provide funding and resources for the development of its drug candidates. The company may also receive royalties from the commercial sales of any successfully developed products. As GlycoMimetics is a clinical-stage company, it does not yet have products on the market and thus does not generate revenue from direct product sales. Instead, its financial performance depends heavily on its ability to secure and maintain strategic partnerships to advance its drug pipeline toward commercialization.

GlycoMimetics Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	153.30M	105.76M	794.00K	7.34M	20.95M	0.00
Gross Profit	148.47M	101.87M	-4.00K	-42.00K	11.79M	-43.86M
EBITDA	43.00M	16.16M	-52.15M	-87.60M	-57.37M	-57.28M
Net Income	42.87M	28.54M	-8.24M	-87.89M	-55.54M	-52.89M
Balance Sheet
Total Assets	129.79M	125.41M	28.44M	55.66M	94.85M	98.55M
Cash, Cash Equivalents and Short-Term Investments	15.04M	11.81M	21.67M	46.85M	79.35M	76.86M
Total Debt	1.58M	1.60M	38.00K	2.38M	1.64M	1.80M
Total Liabilities	25.49M	27.00M	50.13M	14.57M	18.78M	30.22M
Stockholders Equity	68.12M	63.32M	-21.69M	41.09M	76.07M	68.34M
Cash Flow
Free Cash Flow	6.73M	-5.96M	-33.10M	-84.59M	-55.31M	-43.68M
Operating Cash Flow	9.86M	-3.64M	-33.10M	-83.75M	-55.05M	-43.61M
Investing Cash Flow	-26.51M	-19.88M	55.43M	48.19M	9.66M	27.39M
Financing Cash Flow	16.51M	2.10M	-45.01M	49.55M	60.38M	327.00K

GlycoMimetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	kr5.49B	9.89	-63.86%	2.02%	27.11%	26.73%
CAPS	48 Neutral	$8.62M	―	-11.56%	―	-5.81%	39.02%
AKTX	44 Neutral	$31.18M	―	-197.11%	―	―	―
GLYC	40 Underperform	$10.13M	―	-182.66%	―	-100.00%	-0.58%
XTLB	39 Underperform	$14.32M	―	-26.83%	―	―	86.44%
BIVI	38 Underperform	$11.17M	―	-93.23%	―	―	66.72%
ALLR	28 Underperform	$15.98M	―	-383.73%	―	―	99.43%

GlycoMimetics Corporate Events

GlycoMimetics Faces Leadership Changes Amid Board Resignations

On February 19, 2025, GlycoMimetics received a termination notice from Apollomics, ending their Collaboration and License Agreement effective January 2, 2020, which granted Apollomics rights to develop and commercialize uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau, and Taiwan. This termination, effective 90 days post-notice, relieves GlycoMimetics of any material obligations under the agreement. Additionally, on February 21, 2025, several directors, including the CEO and CFO, resigned from GlycoMimetics’ Board, with the CEO and CFO entering into separation and consulting agreements. These changes indicate a significant shift in the company’s leadership structure.